Study of Crohn’s and ulcerative colitis in Seoul
Part of Digestive system clinical trials.
This study looks at how inflammatory bowel disease (Crohn’s disease and ulcerative colitis) affects people in a specific area of Seoul. It mainly focuses on describing patterns and health needs rather than testing a new drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of Crohn’s disease or ulcerative colitis
- If Crohn’s: you meet at least 2 specific medical signs, such as symptoms plus scan or biopsy findings, for at least 2 months
- If ulcerative colitis: you meet all key signs, including ongoing typical symptoms, a typical colon/sigmoidoscopy look, and biopsy inflammation
- Your diagnosis must be classified as Crohn’s or ulcerative colitis (not “inflammatory bowel disease, unclassified”)
- You are from the Korean ethnic group (not other ethnic groups)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how changes in gut bacteria (the microbiome) relate to inflammatory bowel disease, including ulcerative colitis and Crohn disease. It may help researchers understand what might improve symptoms or disease control.
This study collects blood and tissue samples to better understand how the immune system behaves in people with inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis. It aims to advance research rather than test a specific new treatment, and it also enrolls healthy volunteers for comparison.
This study looks at blood and/or tissue “molecular” (cell-level) reasons why treatments don’t fully work in adults with Crohn’s disease or ulcerative colitis. If you are starting a biologic or small-molecule medicine and still have moderate to severe symptoms, you may be able to contribute to research that helps improve future care.
This study tests an oral medication called TAK-279 to see if it can safely reduce inflammation in the bowel for people with moderate to severe Crohn's disease who haven't had success with other treatments.
This study looks for “biomarkers” (lab markers, like substances in blood or tissue) that may predict how Crohn’s disease or ulcerative colitis will go and how patients may respond. It may help doctors choose better monitoring or treatments in the future.
This trial tests a new, gentler way to diagnose Crohn's disease. If you have symptoms like long-lasting diarrhea or belly pain, this study may help find out if you have Crohn's without invasive procedures.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.